Emerging therapies for glycogen storage disease type I.

Published

Journal Article (Review)

Glycogen storage disease type I (GSD I) is caused by deficiency of the glucose-6-phosphatase catalytic subunit in type Ia or of glucose-6-phosphate transporter in type Ib. The cellular bases for disruptions of homeostasis have been increasingly understood in GSD I, including those for anemia, renal failure and neutropenia. Advances in the understanding of cellular abnormalities in GSD I have provided rationales for new therapy, and recent developments in gene therapy have led to potential curative treatments for GSD I. These advances will benefit patients with GSD I in the future, improving both quality of life and survival, as well as illuminating the molecular effects of altered metabolism upon multiple organ systems.

Full Text

Duke Authors

Cited Authors

  • Koeberl, DD; Kishnani, PS; Bali, D; Chen, Y-T

Published Date

  • July 2009

Published In

Volume / Issue

  • 20 / 5

Start / End Page

  • 252 - 258

PubMed ID

  • 19541498

Pubmed Central ID

  • 19541498

Electronic International Standard Serial Number (EISSN)

  • 1879-3061

Digital Object Identifier (DOI)

  • 10.1016/j.tem.2009.02.003

Language

  • eng

Conference Location

  • United States